Sylvester Comprehensive Cancer Center Precision Medicine Conference Highlights New Pathways to Personalized Cancer Care
Prominent academic leaders from the University of Miami and beyond discussed the evolving role of precision oncology at the 3rd Biennial Miami Precision Medicine Conference.
As precision oncology becomes an increasingly defining feature of modern cancer care, clinicians, researchers, patients and patient advocates convened in Miami April 11–12 for the 3rd Biennial Miami Precision Medicine Conference to examine how molecular and data-driven tools are reshaping clinical practice.
Hosted by Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the two-day conference brought together national and international experts to explore how precision medicine is informing decision-making across cancer prevention, diagnosis, treatment and survivorship.
“Precision medicine has moved beyond proof of concept,” said Carmen Calfa, M.D., conference program director, clinical research lead of the Breast Site Disease Group and co-director of Sylvester Survivorship and Supportive Care Institute. “The challenge now is ensuring these tools are applied thoughtfully and consistently so scientific advances translate into meaningful clinical benefit.”
Advancing Clinical Decision-Making Through Molecular Insight
The conference’s scientific program examined how advances in germline and genomic testing, next-generation sequencing, liquid biopsies, multi-omics platforms and artificial intelligence are refining tumor classification, informing therapeutic selection and shaping clinical trial enrollment strategies.
Speakers emphasized that technical capability alone is insufficient. Increasingly complex molecular data must be interpreted within rigorous clinical and multidisciplinary frameworks. A molecular tumor board session illustrated collaborative decision-making among oncologists, pathologists and other specialists, highlighting the expertise required to integrate biomarkers into individualized care plans responsibly.
“Precision oncology isn’t just about having access to advanced testing. It’s about knowing how to interpret that information in the context of each patient,” said Estelamari Rodriguez, M.D., M.P.H., Sylvester’s clinical research lead of the Thoracic Site Disease Group and associate director of outreach. “Conferences like this help clinicians build the confidence and shared language needed to translate very complex data into meaningful clinical decisions.”
She added that artificial intelligence and availability of large data is advancing precision medicine for treatment and patient care.
Patients and Advocates in an Evolving Precision Paradigm
A concurrent patient and advocate track examined the broader implications of precision medicine across the cancer experience, including genetic risk assessment, clinical trial participation and survivorship planning. Sessions underscored the importance of informed engagement as personalized approaches become more fully embedded in routine care.
“When patients understand why certain tests are recommended or how molecular information shapes treatment options, they become active partners in care,” said Dr. Calfa, an associate professor in the Miller School’s Division of Medical Oncology. “That shared understanding is essential as treatments become more individualized.”
Precision Medicine Beyond Targeted Therapy
Speakers noted that precision medicine today extends beyond targeted therapeutics. Increasingly, it informs prevention strategies, early interception, survivorship care and supportive services through a deeper understanding of cancer biology and risk.
“One of the most important roles of academic cancer centers like Sylvester is to bring new targeted therapies from a research laboratory to first-in-human trials to FDA approval,” said Jonathan Trent, M.D., Ph.D., director of Sylvester’s sarcoma molecular research program, associate director clinical research and a professor in the Division of Medical Oncology at the Miller School. “This translational science will lead us closer to a cure for cancer.”
Education, Collaboration and Academic Leadership
By convening clinicians and scientists from both academic and community settings, the conference also highlighted the role of academic cancer centers in advancing education and collaboration. As precision approaches become more widely adopted, disseminating up-to-date, evidence-based knowledge remains essential.
“Our goal is to create a forum where clinicians, researchers and patients can learn from one another,” Dr. Calfa said. “Precision medicine advances fastest when knowledge is shared and applied collaboratively.”
As discoveries continue to accelerate, the 3rd Biennial Miami Precision Medicine Conference underscored both the promise and the complexity of personalized cancer care, reinforcing precision medicine as a defining feature of contemporary oncology.
More from Sylvester Comprehensive Cancer Center
A mother-daughter initiative, “More for Mom,” delivers comfort and support to chemotherapy patients at Sylvester Comprehensive Cancer Center.
Sylvester Comprehensive Cancer Center hosted a survivorship celebration honoring life beyond cancer through connection and supportive care.
A $114,000 Sylvester study tests a self‑guided digital program to improve quality of life for survivors of HPV‑related head and neck cancer.
Sylvester Comprehensive Cancer Center is a host site for the SMART 3RP Lymphoma clinical trial for lymphoma patients.
Tags: cancer care, cancer survivorship, Dr. Carmen Calfa, Dr. Estelamari Rodriguez, Dr. Jonathan Trent, Miami Precision Medicine Conference, personalized medicine, precision medicine, Sylvester Comprehensive Cancer Center, Sylvester Survivorship and Supportive Care Institute